Quick Answer
Black Diamond Therapeutics, Inc. reported Net Income of $22.37 million for fiscal year 2025.
Black Diamond Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | $22.37M +132.1% |
-$69.68M +15.5% |
-$82.44M +9.6% |
-$91.17M +27.4% |
-$125.60M -86.7% |
-$67.25M -90.7% |
| Diluted EPS | $0.39 +130.7% |
-$1.27 +32.4% |
-$1.88 +25.4% |
-$2.52 +27.4% |
-$3.47 -69.3% |
-$2.05 |
| Total Assets | $143.01M +16.6% |
$122.64M -22.7% |
$158.57M +1.5% |
$156.25M -36.9% |
$247.68M -24.9% |
$329.67M +108.3% |
| Cash and Equivalents | $20.99M -42.4% |
$36.44M -35.2% |
$56.22M +63.8% |
$34.31M -47.8% |
$65.80M +90.1% |
$34.60M -77.6% |
| Stockholders Equity | $112.21M +34.7% |
$83.28M -28.7% |
$116.74M +0.9% |
$115.69M -40.9% |
$195.90M -36.3% |
$307.76M +752.6% |
| R&D Expense | $33.56M -34.6% |
$51.31M -13.5% |
$59.35M -7.9% |
$64.44M -33.5% |
$96.83M +100.9% |
$48.21M +121.6% |
| Operating Income | $12.52M +115.9% |
-$78.78M +8.9% |
-$86.46M +6.9% |
-$92.83M +26.8% |
-$126.87M -82.4% |
-$69.57M -137.2% |
| Shares Outstanding | 57.14M +0.9% |
56.64M +9.7% |
51.65M +41.7% |
36.43M +0.6% |
36.23M +0.4% |
36.08M +1513.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$8.50M | +45.4% | +19.5% |
| Diluted EPS | September 30, 2025 | -$0.15 | +46.4% | +21.1% |
| Total Assets | September 30, 2025 | $157.73M | +14.4% | -5.2% |
| Cash and Equivalents | September 30, 2025 | $30.86M | +31.8% | +2.9% |
| Stockholders Equity | September 30, 2025 | $126.15M | +29.5% | -4.9% |
| R&D Expense | September 30, 2025 | $7.44M | -42.4% | -20.2% |
| Operating Income | September 30, 2025 | -$10.98M | +39.4% | +18.2% |
| Shares Outstanding | September 30, 2025 | 56.94M | +0.7% | +0.1% |
- Black Diamond Therapeutics, Inc. reported Net Income of $22.37 million for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +132.1% in Net Income compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported Diluted EPS of $0.39 per share for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +130.7% in Diluted EPS compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported Total Assets of $143.01 million for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +16.6% in Total Assets compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported Cash and Equivalents of $20.99 million for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed a decrease of -42.4% in Cash and Equivalents compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported Stockholders Equity of $112.21 million for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +34.7% in Stockholders Equity compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported R&D Expense of $33.56 million for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed a decrease of -34.6% in R&D Expense compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported Operating Income of $12.52 million for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +115.9% in Operating Income compared to the prior fiscal year.
- Black Diamond Therapeutics, Inc. reported Shares Outstanding of 57.14 million shares for fiscal year 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +0.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: